{"id":"NCT00703326","sponsor":"Eli Lilly and Company","briefTitle":"Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer","officialTitle":"A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08-06","primaryCompletion":"2013-03-31","completion":"2020-11-19","firstPosted":"2008-06-23","resultsPosted":"2014-06-17","lastUpdate":"2021-12-06"},"enrollment":1144,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"ramucirumab (IMC-1121B)","otherNames":["IMC-1121B","LY3009806"]},{"type":"DRUG","name":"docetaxel","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"ramucirumab (IMC-1121B) + docetaxel","type":"EXPERIMENTAL"},{"label":"placebo + docetaxel","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic breast cancer.","primaryOutcome":{"measure":"Progression-Free Survival (PFS)","timeFrame":"Randomization to disease progression or death or until data cutoff of 31 Mar 2013 (up to 56 months)","effectByArm":[{"arm":"Ramucirumab (IMC-1121B) + Docetaxel","deltaMin":9.5,"sd":null},{"arm":"Placebo + Docetaxel","deltaMin":8.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.077"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":21,"exclusionCount":14},"locations":{"siteCount":232,"countries":["United States","Australia","Belgium","Brazil","Canada","Croatia","Czechia","Egypt","Germany","Ireland","Israel","Lebanon","New Zealand","Peru","Poland","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["28950290","28520849","25185099"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":285,"n":752},"commonTop":["Alopecia","Stomatitis","Diarrhoea","Nausea","Fatigue"]}}